Antibodies to IL-6 to inhibit or treat inflammation
View Patent ↗The present invention is directed to therapeutic methods using IL-6 antagonists such as an Ab1 antibody or antibody fragment having binding specificity for IL-6 to prevent or treat disease or to improve survivability or quality of life of a patient in need thereof. In preferred embodiments these patients will comprise those exhibiting (or at risk of developing) an elevated serum C-reactive protein level, reduced serum albumin level, elevated D-dimer or other coagulation cascade related protein(s), cachexia, fever, weakness and/or fatigue prior to treatment. The subject therapies also may include the administration of other actives such as chemotherapeutics, anti-coagulants, statins, and others.
1. A method of inhibiting or treating inflammation associated with elevated interleukin-6 (IL-6) comprising administering an antibody or antibody fragment to a subject in need thereof, wherein the antibody or antibody fragment comprises variable light (VL) chain complementarity determining regions (CDRs) of SEQ ID NO:4, 5 and 6, and variable heavy (VH) chain CDRs of SEQ ID NO:7, 8 or 120, and 9, respectively.
2. The method of claim 1 , wherein the antibody or antibody fragment comprises (a) a VL chain polypeptide sequence which is at least 90% identical to the polypeptide sequences of SEQ ID NO:699, SEQ ID NO:20 or SEQ ID NO:2, and (b) a VH chain polypeptide sequence which is at least 90% identical to the polypeptide sequences of SEQ ID NO:657, SEQ ID NO:19, or SEQ ID NO:3.
3. The method of claim 2 , wherein said antibody or antibody fragment is selected from the group consisting of Fab, Fab′, F(ab′) 2 , Fv, IgNAR, SMIP, camelbodies, nanobodies and scFvs.
4. The method of claim 2 , wherein said antibody or antibody fragment is selected from the group consisting of human, chimeric and humanized antibodies and fragments thereof.
5. The method of claim 1 , wherein the antibody or antibody fragment comprise (a) a VL chain polypeptide sequence which is at least 95% identical to the polypeptide sequences of SEQ ID NO:699, SEQ ID NO:20 or SEQ ID NO:2, and (b) a VH chain polypeptide sequence which is at least 95% identical to the polypeptide sequences of SEQ ID NO:657, SEQ ID NO:19, or SEQ ID NO:3.
6. The method of claim 5 , wherein said antibody or antibody fragment is selected from the group consisting of Fab, Fab′, F(ab′) 2 , Fv, IgNAR, SMIP, camelbodies, nanobodies and scFvs.
7. The method of claim 5 , wherein said antibody or antibody fragment is selected from the group consisting of human, chimeric and humanized antibodies and fragments thereof.
8. The method of claim 1 , wherein the antibody or antibody fragment comprises (a) a VL chain polypeptide sequence which is at least 98% identical to the polypeptide sequences of SEQ ID NO:699, SEQ ID NO:20 or SEQ ID NO:2, and (b) a VH chain polypeptide sequence which is at least 98% identical to the polypeptide sequences of SEQ ID NO:657, SEQ ID NO:19, or SEQ ID NO:3.
9. The method of claim 8 , wherein said antibody or antibody fragment is selected from the group consisting of Fab, Fab′, F(ab′) 2 , Fv, IgNAR, SMIP, camelbodies, nanobodies and scFvs.
10. The method of claim 8 , wherein said antibody or antibody fragment is selected from the group consisting of human, chimeric and humanized antibodies and fragments thereof.
11. The method of claim 1 , wherein the antibody or antibody fragment comprises (a) a VL chain polypeptide sequence which is identical to the polypeptide sequences of SEQ ID NO:699, SEQ ID NO:20 and or SEQ ID NO:2, and (b) a VH chain polypeptide sequence which is identical to the polypeptide sequences of SEQ ID NO:657, SEQ ID NO:19, or SEQ ID NO:3.
12. The method of claim 11 , wherein said antibody or antibody fragment is selected from the group consisting of Fab, Fab′, F(ab′) 2 , Fv, IgNAR, SMIP, camelbodies, nanobodies and scFvs.
13. The method of claim 11 , wherein said antibody or antibody fragment is selected from the group consisting of human, chimeric and humanized antibodies and fragments thereof.
14. The method of claim 1 , wherein said antibody or antibody fragment is selected from the group consisting of human, chimeric and humanized antibodies and fragments thereof.
15. The method of claim 1 , wherein the antibody or antibody fragment has an in vivo half-life of at least about 22 days in a healthy human subject.
16. The method of claim 1 , wherein the antibody or antibody fragment has an in vivo half-life of at least about 25 days in a healthy human subject.
17. The method of claim 1 , wherein the antibody or antibody fragment has an in vivo half-life of at least about 30 days in a healthy human subject.
18. The method of claim 1 , wherein the antibody or antibody fragment has a binding affinity (Kd) for IL-6 of less than about 50 picomolar, or a rate of dissociation (K off ) from IL-6 of less than or equal to 10 −4 S −1 .
19. The method of claim 1 , wherein the antibody or antibody fragment is non-glycosylated.
20. The method of claim 1 , wherein the antibody or antibody fragment contains an Fc region that has been modified to alter effector function, half-life, proteolysis, and/or glycosylation.
21. The method of claim 1 , wherein the antibody or antibody fragment is a human, humanized, single chain, or chimeric antibody.
22. The method of claim 1 , wherein said antibody or antibody fragment further comprises a human Fc.
23. The method of claim 22 , wherein said human Fc is derived from IgG1, IgG2, IgG3, IgG4, IgG5, IgG6, IgG7, IgG8, IgG9, IgG10, IgG11, IgG12, IgG13, IgG14, IgG15, IgG16, IgG17, IgG18 or IgG19.
24. The method of claim 22 , wherein said human Fc is derived from IgG1.
25. The method of claim 1 , which results in the subject's Glasgow Prognostic Score (GPS) being improved.
26. The method of claim 1 , wherein the antibody or antibody fragment is co-administered with another anti-inflammatory agents.
27. The method of claim 1 , wherein the antibody or antibody fragment is co-administered with an antagonist of a factor selected from the group consisting of tumor necrosis factor-alpha, interferon gamma, interleukin 1 alpha, interleukin 1 beta, interleukin 6, proteolysis inducing factor, leukemia-inhibitory factor, IL-2, IL-4, IL-10, IL-12, IL-13, IL-18, IFN-α, IFN-γ, BAFF, CXCL13, IP-10, VEGF, EPO EGF, HRG, Hepatocyte Growth Factor (HGF), Hepcidin, or any combination thereof.
28. The method of claim 1 , wherein the disease is a chronic inflammatory condition.
29. The method of claim 1 , wherein the antibody or antibody fragment comprises (a) a light chain polypeptide sequence which is at least 90% identical to the polypeptide sequences of SEQ ID NO:702 or SEQ ID NO:706, and (b) a heavy chain polypeptide sequence which is at least 90% identical to the polypeptide sequences of SEQ ID NO:704 or SEQ ID NO:708.
30. The method of claim 1 , wherein the antibody or antibody fragment comprises (a) a light chain polypeptide sequence which is at least 95% identical to the polypeptide sequences of SEQ ID NO:702 or SEQ ID NO:706, and (b) a heavy chain polypeptide sequence which is at least 95% identical to the polypeptide sequences of SEQ ID NO:704 or SEQ ID NO:708.
31. The method of claim 1 , wherein the antibody or antibody fragment comprises (a) a light chain polypeptide sequence which is at least 98% identical to the polypeptide sequences of SEQ ID NO:702 or SEQ ID NO:706, and (b) a heavy chain polypeptide sequence which is at least 98% identical to the polypeptide sequences of SEQ ID NO:704 or SEQ ID NO:708.
32. The method of claim 1 , wherein the antibody or antibody fragment comprises D (a) a light chain polypeptide sequence which is identical to the polypeptide sequences of SEQ ID NO:702 or SEQ ID NO:706, and (b) a heavy chain polypeptide sequence which is identical to the polypeptide sequences of SEQ ID NO:704 or SEQ ID NO:708.